KUN-HUEI YEHLin M. T.JIH-LUH TANGCHIH-HSIN YANGWOEI TSAYYAO-CHANG CHEN2020-05-262020-05-2619950007-1048https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028944263&doi=10.1111%2fj.1365-2141.1995.tb08437.x&partnerID=40&md5=f0114ee9c7377f0346ed19f92d19e970https://scholars.lib.ntu.edu.tw/handle/123456789/495169Primary plasma cell leukaemia (PPCL) is a rare form of plasma cell neoplasm. Treatments of PPCL have been most disappointing. A patient with PPCL received high?dose melphalan plus total body irradiation and autologous bone marrow transplantation (ABMT). By using third?complementarity?determining region (CDRIII)?specific probes, minimal residual disease (MRD) was detected in remission marrow, collected 1 month before ABMT. MRD was no longer detected by CDRIII?specific probes 6, 19 and 26 months after transplantation. The patient remained in complete remission up to 59 months after ABMT. Copyright ? 1995, Wiley Blackwell. All rights reserved[SDGs]SDG3cyclophosphamide; doxorubicin; melphalan; prednisone; vincristine; adult; article; autologous bone marrow transplantation; case report; female; human; minimal residual disease; normal human; plasma cell leukemia; priority journal; survival; whole body radiation; Adult; Base Sequence; Bone Marrow Transplantation; Case Report; Disease-Free Survival; DNA Probes; Female; Human; Leukemia, Plasmacytic; Molecular Sequence Data; Neoplasm, Residual; Support, Non-U.S. Gov't; Transplantation, Homologousjournal article10.1111/j.1365-2141.1995.tb08437.x77725342-s2.0-0028944263